Gastro bismol 524 инструкция на русском

Гастрарекс, за счет входящего в его состав метилметионинсульфония хлорида (витамина U), обладает гастропротекторным действием, способствуя защите и укреплению слизистой оболочки желудка и двенадцатиперстной кишки. Обладает антиоксидантной активностью и способствует защите клеток печени.

Метилметионинсульфония хлорид

Гастрарекс содержит S-метилметионинсульфония хлорид — витаминоподобное вещество (витамин U), активированную форму незаменимой аминокислоты – метионина, необходимого для синтеза всех белковых соединений; активно влияет на секреторную функцию желудка.

Влияние на клетки слизистой оболочки желудка и кишечника

Благодаря способности отдавать свои метильные группы, необходимые для процессов синтеза, и влияния на холиновый обмен, метилметионинсульфония хлорид стимулирует выработку муцина клетками слизистой оболочки ЖКТ, что способствует повышению ее защитной функции от агрессивных факторов внутренней и внешней среды и активизирует процессы восстановления клеток слизистой оболочки желудка и кишечника, непосредственно стимулируя процесс регенерации клеток желудка и двенадцатиперстной кишки.

Влияние на кислотность и диспептические проявления

Метилметионинсульфония хлорид метилирует гистамин, который стимулирует продукцию соляной кислоты, превращая его в неактивную форму. Переход гистамина в неактивную форму – метилгистамин, ведет к уменьшению секреции соляной кислоты и снижает вероятность повреждения клеток желудка и кишечника. Вследствие этого уменьшаются типичные желудочно-кишечные нарушения, характерные для избытка гистамина: тяжесть в животе, изжога, вздутие живота и нарушения моторики кишечника. При недостаточной секреции соляной кислоты метилметионинсульфония хлорид стимулирует ее выработку.

Влияние на ЖКТ при воздействии этанола

Метилметионинсульфония хлорид обладает антиоксидантной активностью, задерживая процессы перекисного окисления липидов, и защищает клетки слизистой оболочки желудка от агрессивного воздействия этанола и его производных.

Влияние на клетки печени

Метилметионинсульфония хлорид, обладая липотропным действием, оказывает защитный эффект на клетки печени. Исследования показали, что метилметионинсульфония хлорид снижает уровень общего холестерина и липидов низкой плотности (вредного холестерина) в крови. Стабилизируется проницаемость клеточных мембран, препятствуя замещению тканей печени жировой тканью, улучшается углеводный, белковый и липидный обмен в печени.

Гастрарекс, благодаря входящему в его состав метилметионинсульфония хлориду, способствует:

• укреплению и защите слизистой оболочки желудка и двенадцатиперстной кишки от влияния агрессивных факторов;
• нормализации повышенной или пониженной кислотности желудочного сока;
• улучшению секреторной функции желудка и двенадцатиперстной кишки;
• нормализации моторики желудка и кишечника;
• активации процессов восстановления в слизистой оболочке желудка и кишечника на клеточном уровне;
• уменьшению проявления дискомфорта в ЖКТ;
• улучшению углеводного, белкового и липидного обмена в печени.

Pepto – Bismol (Gastro-Bismol)
(Bismuth Salicylate)
PL 00129/0141
UKPAR
TABLE OF CONTENTS
Lay Summary
Page 2
Scientific discussion
Page 3
Steps taken for assessment
Page 11
Steps taken after authorisation – summary
Page 12
Summary of Product Characteristics
Page 13
Product Information Leaflet and Labelling
Page 17
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
1
PL 00129/0141
Gastro-Bismol, 17.5mg/ml oral suspension
(Bismuth Subsalicylate)
PL 00129/0141
LAY SUMMARY
The MHRA granted Procter & Gamble (Health and Beauty Care) Limited a
Marketing Authorisation (licence) for the medicinal product Gastro-Bismol,
17.5mg/ml oral suspension PL 00129/0141. This product is a Pharmacy only
medicine (P) for upset stomach, indigestion, heartburn and nausea and to control
diarrhoea.
Gastro-Bismol, 17.5mg/ml oral suspension contains the active ingredient Bismuth
Subsalicylate.
The clinical data presented to the MHRA, pre licensing, demonstrated that GastroBismol, 17.5mg/ml oral suspension is essentially similar or equivalent to the approved
product Pepto – Bismol 17.52mg/ml, PL 00364/0025. Gastro-Bismol, 17.5mg/ml oral
suspension can therefore be used interchangeably with Pepto – Bismol of the same
strength.
No new or unexpected safety concerns arose from this application and it was therefore
judged that the benefits of taking Gastro-Bismol, 17.5mg/ml oral suspension outweigh
the risks hence a Marketing Authorisation has been granted.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
2
PL 00129/0141
Gastro-Bismol, 17.5mg/ml oral suspension
(Bismuth Subsalicylate)
PL 00129/0141
SCIENTIFIC DISCUSSION
TABLE OF CONTENTS
Introduction
Page 4
Pharmaceutical assessment
Page 5
Preclinical assessment
Page 7
Clinical assessment (including statistical assessment)
Page 8
Overall conclusions and risk benefit assessment
Page 11
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
3
PL 00129/0141
INTRODUCTION
Based on the review of the data on quality, safety and efficacy the UK granted
marketing authorisations for the medicinal product Gastro-Bismol, 17.5mg/ml oral
suspension PL 00129/0141 to Procter & Gamble (Health and Beauty Care) Limited on
17th January 2006.
This application was submitted as an abridged application according to article 10.1(i)
of Directive 2001/83/EC, claiming essential similarity to the original product Pepto –
Bismol 17.52mg/ml PL 00364/0025.
The products contain the active ingredient bismuth subsalicylate and are indicated for
upset stomach, indigestion, heartburn and nausea and to control diarrhoea.
The demulcent base provides a protective coating of the lower oesophagus and a
partial coating in the stomach and holds the bismuth subsalicylate in suspension.
Bismuth subsalicylate exerts an anti-diarrhoeal effect through several different
mechanisms (a) in vitro and human studies demonstrated an antimicrobial effect
against a wide variety of enteric pathogens that cause diarrhoea and food poisoning
(b) human and animal studies demonstrated a binding and inactivation of bacterial
toxins and bile acids (c) animal studies demonstrated an inhibition of secretion and
stimulation of absorption thereby reducing fluid in the intestine and (d) human studies
demonstrated a decreasing GI motility or transit time.
The applicant for Gastro-Bismol, 17.5mg/ml has provided bibliographic published
literature on the availability, efficacy and safety of this fixed dose bismuthsubsalicylate combination. No new clinical studies are submitted.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
4
PL 00129/0141
PHARMACEUTICAL ASSESSMENT
Composition
The proposed suspension product has evolved from the existing product, PeptoBismol and infact the dossier refers to Pepto-Bismol rather than Gastro-Bismol. The
product composition is identical to the currently licensed product, Pepto-Bismol with
PL: 00364/0025. The composition is defined. The strength of the oral suspension is
17.5mg/ml. The excipients present are aluminium magnesium silicate,
methylcellulose, methyl salicylate, salicylic acid, saccharin sodium, sodium salicylate,
amaranth (E123), sorbic acid (E200), benzoic acid (E210) and purified water.
The oral suspension is presented in either a 120, 240 or 480ml PET bottle with white
polypropylene child resistant closure. A polystyrene dosing cup is shrink wrapped
onto the sealed bottle.
Active substance
The active drug substance Bismuth Subsalicylate is the subject of a PhEur
monograph. This source of active has been used in a licensed product (PL:
00364/0025) in the UK since 18/07/1979.
Critical manufacturing process parameters have been validated and form part of the
in-process controls. This is supported by process validation data.
As to the QC during manufacture, starting materials with suitable specifications,
compendial where appropriate, are used. Impurities are identified, tested and
controlled in the drug substance.
Batch analyses are provided for the production scale batches of bismuth subsalicylate.
These comply with PhEur and support the proposed drug substance specification.
Synthesis of the drug substance from the designated starting material has been
adequately described and appropriate in-process controls and intermediate
specifications are applied. Satisfactory specification tests are in place for all starting
materials and reagents and these are supported by relevant certificates of analysis.
An appropriate specification is provided for bismuth subsalicylate.
Analytical methods have been appropriately validated and are satisfactory for
ensuring compliance with the relevant specifications.
Appropriate proof of structure has been supplied for the active pharmaceutical
ingredient.
All potential known impurities have been identified and characterised and appropriate
tests for their control are included in the specification.
Other ingredients
Other ingredients in the drug product are compendial grade, being PhEur or USP as is
the case for aluminium magnesium silicate. This may be considered acceptable as
commercially available functionality material. All materials are tested fully or for
identity as a minimum when accompanied by certificate of analysis.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
5
PL 00129/0141
Satisfactory specifications and certificates of analysis have been provided for the
packaging components.
There are no materials that are a risk of TSE or BSE in this product.
Product development and finished product
Adequate in-process controls are exercised to achieve a homogeneous suspension.
Assay and identification is by a validated method and is acceptable.
Control tests on the finished product include release and shelf life specifications.
Batch analysis is also provided and the results support the proposed specification.
Satisfactory batch formulae have been provided for the manufacture of the product
along with an appropriate account of the manufacturing process. The manufacturing
process has been validated and appropriate in-process controls are applied.
The finished product specification proposed is acceptable and the analytical methods
used have been suitably validated. Batch analysis data has demonstrated compliance
with the proposed release specification.
Stability of the product
Results of stability studies are acceptable. These data support a shelf-life of 28 months
for product labelled with ‘Do not store above 25°C’. The stability data have been
generated according to ICH guidelines.
SPC, PIL, Labels
The SPC, PIL and Labels are pharmaceutically acceptable.
CONCLUSION
It is recommended that Marketing Authorisations are granted for this application.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
6
PL 00129/0141
PRECLINICAL ASSESSMENT
This application for a bibliographic product claims essential similarity to Pepto –
Bismol 17.52mg/ml PL 00364/0025, which has been licensed within the EEA for over
10 years.
New preclinical data are not required for this type of application therefore no new
preclinical data have been submitted.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
7
PL 00129/0141
CLINICAL ASSESSMENT
INTRODUCTION AND BACKGROUND
The demulcent base provides a protective coating of the lower oesophagus and a
partial coating in the stomach and holds the bismuth subsalicylate in suspension.
Bismuth subsalicylate exerts an anti-diarrhoeal effect through several different
mechanisms (a) in vitro and human studies demonstrated an antimicrobial effect
against a wide variety of enteric pathogens that cause diarrhoea and food poisoning
(b) human and animal studies demonstrated a binding and inactivation of bacterial
toxins and bile acids (c) animal studies demonstrated an inhibition of secretion and
stimulation of absorption thereby reducing fluid in the intestine and (d) human studies
demonstrated a decreasing GI motility or transit time.
This is a bibliographic abridged application for an oral suspension containing
17.5mg/ml of Bismuth Subsalicylate.
This application is submitted under the provisions of Directive 2001/83/EC Article 10
1 (a)(ii), claiming that the products are essentially similar to Pepto – Bismol
17.52mg/ml PL 00364/0025, that was authorised in the UK on the 18th July 1979.
The applicant has provided bibliographic published literature on the availability,
efficacy and safety of this fixed dose bismuth-salicylate combination. No new
clinical studies are submitted. This is considered satisfactory.
2.
INDICATIONS
The proposed indication is:
For upset stomach, indigestion, heartburn and nausea. Controls diarrhoea.
This is considered satisfactory and to be fully consistent with the SPC for Pepto –
Bismol 17.52mg/ml PL 00364/0025.
3.
DOSE & DOSE SCHEDULE
The proposed dose and dosage schedules for this product are satisfactory
4.
TOXICOLOGY
No new data were submitted.
5.
CLINICAL PHARMACOLOGY
No new data were submitted for this product.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
8
PL 00129/0141
6.
EFFICACY
No new data were submitted for this product.
7.
SAFETY
No new data were submitted for this product.
8.
EXPERT REPORT
The applicant has submitted an expert report by an appropriately qualified physician.
9.
SUMMARY OF PRODUCT CHARACTERISTICS
Contraindications: Satisfactory
Special warnings: Satisfactory
Interactions: Satisfactory
Pregnancy: Satisfactory
Driving: Satisfactory
Undesirable effects: Satisfactory
Overdose: Satisfactory
Pharmacology, pre-clinical safety: Satisfactory
10.
PATIENT INFORMATION LEAFLET
Not applicable
11.
LABELLING
The labelling is considered satisfactory.
12.
CONCLUSIONS
The grant of a marketing authorisation is recommended for this product.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
9
PL 00129/0141
OVERAL CONCLUSION AND RISK BENEFIT ASSESSMENT
QUALITY
The important quality characteristics of Gastro-Bismol 17.5mg/ml oral suspension are
well defined and controlled. The specifications and batch analytical results indicate
consistency from batch to batch. There are no outstanding quality issues that would
have a negative impact on the benefit/risk balance.
PRECLINICAL
New preclinical data are not required for this type of application therefore no new
preclinical data have been submitted.
EFFICACY
No new or unexpected safety concerns arise from this application.
The SPC, PIL and labelling are satisfactory and consistent with that for Pepto Bismol oral suspension.
RISK BENEFIT ASSESSMENT
The quality of the product is acceptable and no new preclinical or clinical safety
concerns have been identified. Extensive clinical experience with Bismuth
Subsalicylate is considered to have demonstrated the therapeutic value of the
compound. The risk benefit is therefore considered to be positive.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
10
PL 00129/0141
Gastro-Bismol, 17.5mg/ml oral suspension
(Bismuth Subsalicylate)
PL 00129/0141
STEPS TAKEN FOR ASSESMENT
1
The MHRA received the marketing authorisation application on the 11th
September 2002.
2
Following standard checks and communication with the applicant the MHRA
considered the application valid on the 2nd of October 2002.
3
Following assessment of the application the MHRA requested further
information relating to the clinical dossier on 29 November 2002, and further
information relating to the quality dossier on 29 November 2002.
4
The applicant responded to the MHRA’s requests, providing further information
on 31st January 2003, and again on 3rd February 2003.
5
Following assessment of the response the MHRA requested further additional
information relating to the pharmaceutical dossier on 19th February 2003, 11th
April 2003, 1st July 2004, 25th February 2005. Further requests were made
relating to the medical dossier on 19th August 2003.
6
The applicant responded, providing further information, on 11th April 2003, 27th
May 2004, 29th June 2004, 5th October 2004, 27th June 2005.
7
The application was determined on the 20th January 2006.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
11
PL 00129/0141
Gastro-Bismol, 17.5mg/ml oral suspension
(Bismuth Subsalicylate)
PL 00129/0141
STEPS TAKEN AFTER AUTHORISATION - SUMMARY
Date
Application
submitted type
MHRA PAR Gastro-Bismol,
Scope
Outcome
17.5mg/ml oral suspension (Bismuth Subsalicylate)
12
PL 00129/0141
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Gastro-Bismol, 17.5mg/ml oral suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of suspension contains 17.5mg Bismuth Subsalicylate
One 30ml dose contains 525mg Bismuth Subsalicylate
For excipients see 6.1
3.
PHARMACEUTICAL FORM
Oral suspension
Pink, viscous liquid suspension
4.
CLINICAL PARTICULARS
4.1.
Therapeutic Indications
For upset stomach, indigestion, heartburn and nausea. Controls diarrhoea.
4.2.
Posology and Method of Administration
Adults and children 16 years and over:
30ml in dosing cup provided, or 6 x 5ml spoonfuls
Repeat dose every 1/2 to 1 hour if needed. No more than 8 doses to be taken in 24 hours.
Do not exceed the recommended dose, shake bottle before use
For oral use only.
4.3.
Contra-indications
Gastro-Bismol should not be used by patients hypersensitive to Aspirin or other salicylates.
Gastro-Bismol should not be used by patients hypersensitive to any ingredient in the
formulation.
Gastro-Bismol should not be used by children under 16 years of age.
4.4.
Special Warnings and Precautions for Use
Do not take with aspirin or other salicylates
Gastro-Bismol should not be used by those aged under 16 due to a possible association
between salicylates and Reye's syndrome, a very rare but very serious disease
Caution should be exercised by patients taking medicines for anti-coagulation (thinning of
the blood), diabetes or gout.
Gastro-Bismol should not be used if symptoms are severe or persist for more than 2 days.
Do not exceed the recommended dose.
Keep all medicines out of reach and sight of children.
4.5.
Interactions with other Medicaments and other forms of Interaction
Gastro-Bismol contains salicylates therefore care should be exercised if receiving drugs to
thin the blood (anticoagulant therapy) or oral therapy for diabetes or treatment for gout.
4.6.
Pregnancy and Lactation
There are no adequate data concerning the use of Gastro-Bismol in pregnant women.
Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal
development, parturition and postnatal development. The potential risk for humans is
unknown.
Gastro-Bismol should not be used during pregnancy and lactation unless clearly necessary.
4.7.
Effects on Ability to Drive and Use Machines
None.
4.8.
Undesirable Effects
Black tongue is common (>1/100, <1/10) undesired effect, the undesired effect of black
stool is very common (>1/10).
4.9.
Overdose
Bismuth intoxication may present as an acute encephalopathy with confusion, myoclonic
movements, tremor, dysarthria and walking and standing disorders. Bismuth intoxication
may also cause gastrointestinal disturbances, skin reactions, discolouration of mucous
membranes, and renal dysfunction as a result of acute tubular necrosis. Treatment includes
gastric lavage, purgation and hydration. Chelating agents may be effective in the early
stages following ingestion and haemodialysis may be necessary.
Overdose of Gastro-Bismol may also give symptoms of salicylate intoxification e.g.
dizziness, tinnitus, sweating, nausea, headache. If symptoms occur, use of Gastro-Bismol
should be discontinued. Management of overdose is the same as that for salicylate overdose.
5.
PHARMACOLOGICAL PROPERTIES
5.1.
Pharmacodynamic Properties
Pharmacotherapeutic code: ATC code A07B B
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
14
PL 00129/0141
The demulcent base provides a protective coating of the lower oesophagus and a partial
coating in the stomach which holds the bismuth subsalicylate in suspension.
Bismuth subsalicylate exerts an anti-diarrhoeal effect through several different mechanisms
(a) in vitro and human studies demonstrated an antimicrobial effect against a wide variety of
enteric pathogens that cause diarrhoea and food poisoning (b) human and animal studies
demonstrated a binding and inactivation of bacterial toxins and bile acids (c) animal studies
demonstrated an inhibition of secretion and stimulation of absorption thereby reducing fluid
in the intestine and (d) human studies demonstrated a decreasing GI motility or transit time.
5.2.
Pharmacokinetic Properties
Bismuth subsalicylate is converted to bismuth carbonate and sodium salicylate in the small
intestine.
The oral bioavailability of bismuth administered as Bismuth subsalicylate is extremely low.
Very little is known about bismuth distribution in human tissue. Renal clearance is the
primary route of elimination for absorbed bismuth, however biliary clearance may also have
a role. The remainder is eliminated as insoluble bismuth salts in the faeces. Following the
maximum recommended daily adult dose, the mean biological half-life is approximately 33
hours and peak plasma bismuth levels remain below 35ppb.
Salicylate is absorbed from the intestine and rapidly distributed to all body tissues. Peak
plasma levels after maximum recommended daily dosing are about 110 micrograms/ml.
Salicylate is rapidly excreted from the body and has a mean biological half life of
approximately 4 - 5.5 hours.
5.3.
Preclinical Safety Data
There are no pre-clinical safety data of relevance to health professionals, other than those
already included in other sections of the SPC
6.
PHARMACEUTICAL PARTICULARS
6.1.
List of Excipients
Aluminium magnesium silicate
Methylcellulose
Methyl salicylate
Salicylic acid
Saccharin sodium
Sodium salicylate
Amaranth (E123)
Sorbic Acid
Benzoic Acid
Purified water
6.2.
Incompatibilities
None stated.
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
15
PL 00129/0141
6.3.
Shelf Life
28 months
6.4.
Special Precautions for Storage
Do not store above 25°C.
6.5.
Nature and Contents of Container
120, 240, 480ml PET bottle with white polypropylene child resistant closure. Polystyrene
dosing cup is shrink wrapped onto the sealed bottle.
6.6.
Instruction for Use/Handling
Shake bottle well before use.
7.
MARKETING AUTHORISATION HOLDER
Procter & Gamble (Health & Beauty Care) Limited
The Heights
Brooklands
Weybridge
Surrey
KT13 0XP
8.
MARKETING AUTHORISATION NUMBER
PL 00129/0141
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
20/01/2006
10
DATE OF REVISION OF THE TEXT
20/01/2006
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
16
PL 00129/0141
Gastro-Bismol Label and Leaflet
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
17
PL 00129/0141
Gastro-Bismol Label and Leaflet
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
18
PL 00129/0141
Gastro-Bismol Label and Leaflet
MHRA PAR Gastro-Bismol,
17.5mg/ml oral suspension (Bismuth Subsalicylate)
19
PL 00129/0141